MADRID and MUMBAI, India, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication solutions, today announced the planned launch of a Mumbai office, its first in India. This new presence will be staffed by a local team and supported by a newly formed partnership with Citadel Global, a trusted value-added distributor (VAD) with deep expertise in national and enterprise-scale cybersecurity and identity so ...

Core Insights - BIO-key International, Inc. has formed a strategic partnership with Visualforma to enhance digital identity and access management for Portuguese municipal councils, focusing on cybersecurity and public digital services [1][5][7] Group 1: Partnership Details - Visualforma will spearhead the nationwide implementation of BIO-key's Identity and Access Management (IAM) and biometric authentication technologies across over 250 government organizations in Portugal [2] - The partnership aims to secure access to critical digital services, enhance cybersecurity controls, and ensure regulatory compliance within municipal administrations, educational institutions, and healthcare entities [2][4] Group 2: Implementation and Impact - The agreement includes deploying BIO-key's technologies in a major tourist city, addressing security and scalability needs for high-volume citizen and visitor services [3] - BIO-key's IAM and biometric solutions have already been operationalized in selected municipal environments, serving as reference architectures for further deployments [4] Group 3: Company Profiles - Visualforma is a well-established technology integrator in Portugal, recognized for its expertise in digital transformation and cybersecurity, with over 30 years of experience in the public sector [9] - BIO-key International specializes in biometric-centric IAM solutions, securing access for over 40 million users and offering various authentication methods, including phoneless and passwordless options [10]

matejmo/iStock via Getty Images The following segment was excerpted from the Artisan Mid Cap Value Fund Q4 2025 Commentary. The portfolio slightly outperformed the Russell Midcap® Value Index in Q4. As we have noted in prior quarterly portfolio letters, our investment style ...

Key Takeaways BIO's Clinical Diagnostics returned to normalized growth, supported by strong platforms and automation up. BIO generates 59% of its revenues internationally, led by Europe, with gradual funding improvements expected.BIO faces currency headwinds, as inflation, China policy shifts and a strong dollar pressure revenues. Bio-Rad Laboratories, Inc. (BIO) is well-poised to grow in the upcoming quarters, given the demand for its quality control and immunology products in Clinical Diagnostics. In addi ...

Core Viewpoint - Bio-Rad Laboratories, Inc. is actively engaging with analysts and investors at the J.P. Morgan's 44th Annual Healthcare Conference, indicating a focus on investor relations and market presence [1] Company Overview - Bio-Rad Laboratories, Inc. is recognized as a global leader in life science research and clinical diagnostics products [1] Event Details - The one-on-one meetings with analysts and investors will take place during the J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, from January 12-15, 2026 [1]

Core Insights - The portable microplate reader market is experiencing rapid growth driven by the increasing demand for point-of-care testing (POCT), ongoing investment in biopharmaceutical research, and the advancement of grassroots healthcare in emerging markets [4][10] - The market is highly concentrated, dominated by a few major players such as Thermo Fisher Scientific, BIO-RAD, and PerkinElmer, which have established strong market barriers through brand reputation and extensive sales networks [4][9] Market Trends and Drivers - The key drivers for the growth of the portable microplate reader market include the significant expansion of POCT demand, particularly in grassroots healthcare and emergency response scenarios [10] - Continuous investment in biopharmaceutical and life sciences research, along with advancements in detection technology towards miniaturization, automation, and user-friendliness, are also contributing to the market's growth [10] Opportunities and Challenges - Government support for precision medicine and public health emergency capabilities presents clear market opportunities, especially in infectious disease monitoring and bedside diagnostics [5] - However, increasing regulatory scrutiny and stringent medical device approval processes raise market entry barriers and costs, posing challenges for companies [5] Market Size and Growth Projections - According to QYResearch, the global portable microplate reader market is expected to reach USD 1.05 billion by 2031, with a compound annual growth rate (CAGR) of 4.5% in the coming years [5] Competitive Landscape - The top five manufacturers, including Thermo Fisher Scientific, BIO-RAD, and PerkinElmer, hold approximately 60% of the market share, indicating a highly concentrated competitive environment [9] Future Industry Opportunities - Future opportunities lie in upgrading grassroots healthcare systems in emerging markets and penetrating non-traditional clinical fields such as veterinary, food safety, and environmental monitoring [12] - The integration of artificial intelligence and IoT technologies for smart interpretation and remote data management is expected to create new application scenarios and business models [12]

Core Insights - BIO-key International, Inc. has secured a significant deployment with a major defense-sector security organization in the Middle East, enhancing its presence in high-assurance government and defense environments [1][2]. Group 1: Deployment Details - The contract is one of BIO-key's largest security-sector deployments in the region, aimed at strengthening access security and streamlining credential management through biometric-based authentication without reliance on mobile devices or hardware tokens [2]. - The deployment is facilitated by a strategic partnership with Cloud Distribution, a Saudi-based Value-Added Distributor, which combines BIO-key's IAM solutions with local cybersecurity expertise [3]. Group 2: Strategic Commitment - The deployment underscores BIO-key's commitment to supporting national security and critical infrastructure protection in the Middle East, reflecting the trust in its technology for securing sensitive environments [4]. Group 3: Company Overview - BIO-key is a leader in biometric-centric, multi-factor identity and access management (IAM) software, securing access for over 40 million users and offering various authentication options, including phoneless, tokenless, and passwordless solutions [5].

Core Insights - Bio-Rad Laboratories reported its third-quarter earnings, achieving revenue of $653 million, which represents a modest year-over-year increase of 0.5%. Net income, on a non-GAAP basis, rose by 8% to just under $61 million, translating to an adjusted earnings per share of $2.26. Despite these results beating analyst expectations, the stock experienced a decline of over 3% following the report, which was more significant than the S&P 500's 0.9% drop [1][2][3][6]. Financial Performance - Revenue for Q3 was $653 million, a slight increase of 0.5% year-over-year [2]. - Non-GAAP net income increased by 8% to just under $61 million, with an adjusted earnings per share of $2.26 [2]. - Analyst consensus had projected revenue of $652.2 million and adjusted earnings of $1.95 per share, indicating that Bio-Rad's performance exceeded these expectations [3]. Market Reaction - The stock market reacted negatively to Bio-Rad's earnings report, leading to a decline of over 3% in its share price, despite the company beating both revenue and earnings estimates [1][6]. Future Guidance - Bio-Rad maintained its guidance for 2025, forecasting revenue growth to be flat to 1% above the 2024 results. The company also indicated that its adjusted operating margin is expected to be between 12% and 13% [3].

Core Insights - Bio-Rad Laboratories, Inc. reported Q3 2025 adjusted EPS of $2.26, missing estimates by 1.74% but showing an 11.9% increase year over year [1][8] - The company's revenues reached $653 million, exceeding expectations by 0.24% and reflecting a 0.5% year-over-year growth [3][8] - Bio-Rad's gross margin contracted by 219 basis points to 52.6%, while operating profit increased by 1.2% [5][8] Financial Performance - The GAAP loss was reported at $12.70 per share, a significant decline from EPS of $23.34 a year ago [2] - Gross profit decreased by 3.5% to $343.4 million, with operating expenses down 4.6% year over year [5] - Cash and cash equivalents at the end of Q3 were $1.42 billion, up from $1.37 billion at the end of Q2 [6] Segment Analysis - Life Science segment sales totaled $261.8 million, a 0.3% increase year over year, but down 1.5% at constant exchange rates [4] - Clinical Diagnostics segment net sales were $391.2 million, up 0.6% year over year, with a decline of 1.8% at constant exchange rates due to lower reimbursement rates in China [4] Guidance and Outlook - Bio-Rad reiterated its full-year 2025 guidance, projecting adjusted, currency-neutral revenue growth of approximately 0-1% [9] - The adjusted operating margin for the full year is expected to be between 12% and 13% [9] - The company anticipates a return to growth in the Diagnostics segment in Q4, with improvements expected from the quality controls portfolio [11]

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share, but showing an increase from $2.01 per share a year ago [1][2]. Financial Performance - The company posted revenues of $653 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.24% and showing a slight increase from $649.73 million year-over-year [3]. - The earnings surprise for the quarter was -1.74%, while the previous quarter saw a positive surprise of +35.23% with actual earnings of $2.61 compared to an expected $1.93 [2]. Market Performance - Bio-Rad shares have increased by approximately 0.6% since the beginning of the year, in contrast to the S&P 500's gain of 17.2% [4]. - The current Zacks Rank for Bio-Rad is 4 (Sell), indicating expectations of underperformance in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.57 on revenues of $693.11 million, and for the current fiscal year, it is $10.02 on revenues of $2.58 billion [8]. - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [9].